Macugen Market Report 2026

Macugen Market Overview

• The Macugen market growth in the historic period has been driven by rising prevalence of age-related macular degeneration, increasing diagnosis of diabetic eye disorders • Market expansion is supported by increasing demand for extended-release ocular formulations, growing investments in retinal disease research • Growth Driver: The Role Of AMD Prevalence In Driving Market Growth • Market Trend: Emerging Role Of Gene Therapy In Transforming The Market • North America was the largest region in 2025.

What Is Covered Under Macugen Market?

Macugen (pegaptanib sodium) is an anti-vascular endothelial growth factor (VEGF)medication used to treat retinal conditions by inhibiting the growth of abnormal blood vessels in the eye. Its purpose is to reduce vision loss and prevent further damage caused by these abnormal blood vessels. The recommended dosage of Macugen is 0.3 mg, administered once every six weeks by an ophthalmologist under sterile conditions. The main indication types of macugen are wet AMD (age-related macular degeneration) and diabetic macular edema. Wet age-related macular degeneration (wet AMD) is a progressive eye condition where abnormal blood vessels grow under the retina, leading to vision loss in the central field of vision. These are available in different formulations, such as intravitreal injection and extended-release. It is distributed through hospitals and clinics, as well as retail and specialty pharmacies. Also, it is used by several end users, including adult patients and geriatric patients.

What Is The Macugen Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for extended-release ocular formulations, growing investments in retinal disease research, rising adoption of personalized ophthalmic treatments, expansion of aging population eye care services, increasing focus on reducing injection frequency. Major trends in the forecast period include increasing use of targeted anti-vegf therapies, rising adoption of intravitreal injection treatments, growing focus on vision preservation therapies, expansion of retinal disease management protocols, enhanced emphasis on long-term treatment efficacy.

Global Macugen Market Segmentation

1) By Indication: Wet AMD(Age-Related Macular Degeneration (AMD)), Diabetic Macular Edema 2) By Formulation: Intravitreal Injection, Extended-Release Formulations 3) By Distribution Channel: Hospitals And Clinics, Retail And Specialty Pharmacies 4) By End User: Adult Patients, Geriatric Patients

What Are The Drivers Of The Macugen Market?

The rising prevalence of age-related macular degeneration (AMD) is expected to propel the growth of the macugen market going forward. Age-related macular degeneration (AMD) is a progressive eye condition affecting the macula, the central part of the retina responsible for clear and detailed vision. The rising prevalence of age-related macular degeneration (AMD) is attributed to an aging global population, increased life expectancy, and lifestyle factors such as smoking, poor diet, and prolonged exposure to ultraviolet (UV) light. Macugen is beneficial for age-related macular degeneration (AMD), which inhibits vascular endothelial growth factor (VEGF), reduces abnormal blood vessel growth and leakage in the retina, and helps preserve vision and slow disease progression. For instance, in May 2023, according to an article published by the National Center for Biotechnology Information, a US-based National Institutes of Health government agency, in 2040, approximately 288 million individuals are projected to be affected by age-related macular degeneration (AMD). Therefore, the rising prevalence of age-related macular degeneration (AMD) is driving the growth of the macugen industry. The rise in focus on eye care is set to propel the growth of the macugen market moving forward. Eye care refers to the practices and treatments to maintain or improve vision and the eyes' health. The rise in focus on eye care is attributed to the increasing prevalence of eye conditions, aging populations, and greater awareness of the importance of vision health. Macugen is beneficial for eye care as it helps treat age-related macular degeneration (AMD) by inhibiting the growth of abnormal blood vessels in the retina, which can prevent vision loss and improve visual acuity. For instance, in November 2023, according to an article published by Nature, a UK-based journal, in August 2024, according to the Welsh Government, a United Kingdom-based government organization, in 2023-24 the number of sight tests paid for by the NHS in Wales increased to a record high of just over 841,000, representing a 6.6% increase compared to 2022-23. Therefore, the rise in focus on eye care is driving the growth of the macugen industry.

Key Players In The Global Macugen Market

Major companies operating in the macugen market are Bausch + Lomb Inc

Global Macugen Market Trends and Insights

The key trend in the macugen market is the development of gene therapy. Gene therapy involves introducing genetic material into a patient's cells to treat or prevent disease, specifically targeting age-related macular degeneration (AMD). For instance, in 2023, Regenxbio, a U.S.-based biotechnology company, launched RGX-314, a gene therapy product designed to deliver a gene encoding for an anti-VEGF protein directly into the eye. This innovative treatment aims to provide long-lasting effects by reducing the need for frequent injections. Unique features of RGX-314 include its potential for a single administration, which could significantly improve patient compliance, and its ability to target the underlying causes of AMD rather than just managing symptoms. These advancements position companies favorably within the evolving landscape of ocular therapies.

Regional Insights

North America was the largest region in the macugen market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Macugen Market?

The macugen market consists of sales of pegaptanib sodium injections and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Macugen Market Report 2026?

The macugen market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the macugen industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.